Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Depreciation and Depletion (2016 - 2017)

Tenax Therapeutics' Depreciation and Depletion history spans 7 years, with the latest figure at $2621.0 for Q4 2017.

  • For Q4 2017, Depreciation and Depletion fell 33.68% year-over-year to $2621.0; the TTM value through Dec 2017 reached $13621.0, up 244.66%, while the annual FY2023 figure was $7570.0, 47.19% up from the prior year.
  • Depreciation and Depletion for Q4 2017 was $2621.0 at Tenax Therapeutics, down from $4000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $23000.0 in Q1 2013 and bottomed at -$10000.0 in Q3 2016.
  • The 5-year median for Depreciation and Depletion is $14918.0 (2015), against an average of $12261.6.
  • The largest annual shift saw Depreciation and Depletion plummeted 40.91% in 2015 before it surged 140.0% in 2017.
  • A 5-year view of Depreciation and Depletion shows it stood at $23000.0 in 2013, then decreased by 8.7% to $21000.0 in 2014, then plummeted by 38.1% to $13000.0 in 2015, then tumbled by 69.6% to $3952.0 in 2016, then crashed by 33.68% to $2621.0 in 2017.
  • Per Business Quant, the three most recent readings for TENX's Depreciation and Depletion are $2621.0 (Q4 2017), $4000.0 (Q3 2017), and $3000.0 (Q2 2017).